Please check your internet connection and try again.
## TUSQ-QD
### Overview
TUSQ-QD is a combination product containing **tusso** (an opioid cough suppressant) and **qd** (an expectorant). The exact chemical names and formulations for tusso are not publicly available, and "qd" is not a recognized pharmaceutical ingredient. This response will proceed assuming "tusso" refers to a dextromethorphan-based cough suppressant and "qd" is a placeholder for an expectorant like guaifenesin, as this is a common combination. **The lack of specific, verifiable active ingredients for "tusso" and "qd" necessitates extreme caution and confirmation of the actual product composition.**
### Primary Indications
* Symptomatic relief of cough and chest congestion associated with the common cold, bronchitis, or other respiratory conditions.
### Adult Dosing
* **Tusso (assumed Dextromethorphan):** 10 mg to 20 mg orally every 4 to 6 hours as needed. Maximum dose typically 120 mg per 24 hours.
* **QD (assumed Guaifenesin):** 200 mg to 400 mg orally every 4 hours as needed. Maximum dose typically 2400 mg per 24 hours.
* **Combined Product:** Dosing will depend on the specific formulation. **Consult the product labeling for exact strengths and dosing intervals.**
### Pediatric Dosing
* **Tusso (assumed Dextromethorphan):**
* 6 to <12 years: 5 mg to 10 mg orally every 4 to 6 hours. Maximum dose typically 60 mg per 24 hours.
* <6 years: **Not recommended without specific product labeling and physician guidance due to risk of serious adverse events.**
* **QD (assumed Guaifenesin):**
* 6 to <12 years: 100 mg to 200 mg orally every 4 hours. Maximum dose typically 1200 mg per 24 hours.
* <6 years: **Consult product labeling and physician guidance.** Dosing may vary.
* **Combined Product:** **Dosing must be based on the specific product formulation and the child's weight and age. Consult product labeling and pediatrician.**
### Dose Adjustments
* **Hepatic Impairment:** Caution advised. May require dose reduction. Specific guidelines are not established for this combination.
* **Renal Impairment:** No specific dose adjustments are typically recommended for dextromethorphan or guaifenesin unless severe.
### Contraindications
* Hypersensitivity to dextromethorphan or guaifenesin.
* Use within 14 days of MAOI therapy (for dextromethorphan due to risk of serotonin syndrome).
* Acute asthma exacerbations.
* Persistent or chronic cough (e.g., due to smoking, emphysema) where cough is necessary for airway clearance.
* **Use in children under 6 years of age for cough suppression is generally not recommended due to potential for serious harm.**
### Adverse Effects
* **Common:** Drowsiness, dizziness, nausea, vomiting, constipation.
* **Less Common/Serious:** Serotonin syndrome (especially with concomitant serotonergic agents), respiratory depression (rare at therapeutic doses but increased with overdose or in specific populations), confusion, hallucinations, abuse/dependence (with prolonged high-dose use).
### Key Drug Interactions
* **Serotonergic Agents (SSRIs, SNRIs, triptans, etc.):** Increased risk of serotonin syndrome with dextromethorphan.
* **MAOIs:** Contraindicated within 14 days of dextromethorphan use due to risk of hypertensive crisis or serotonin syndrome.
* **CNS Depressants (alcohol, benzodiazepines, opioids):** Additive sedative effects.
* **CYP2D6 Inhibitors (e.g., fluoxetine, paroxetine, quinidine):** May increase dextromethorphan plasma concentrations, increasing risk of toxicity.
### Monitoring
* Assess cough frequency and severity.
* Monitor for adverse effects, particularly drowsiness, confusion, and signs of serotonin syndrome.
* Evaluate effectiveness of expectoration.
### Clinical Pearls
* **The identity and safety profile of "tusso" and "qd" require definitive verification from the product's official labeling or manufacturer.** The information provided assumes common ingredients for similar products.
* Tusso-QD is for symptomatic relief only and does not treat the underlying cause of the cough.
* Encourage adequate fluid intake to help thin mucus, especially when using expectorants.
* Avoid concomitant use of other dextromethorphan-containing products to prevent overdose.
* Advise patients to avoid driving or operating heavy machinery if drowsiness occurs.
***
**Disclaimer:** This information is intended for healthcare professionals and is based on the assumed active ingredients. It is not a substitute for professional medical advice. Always consult the most current prescribing information, product labeling, or a pharmacist for definitive guidance before making any treatment decisions. The composition of TUSQ-QD must be confirmed.
